跳至主要内容
临床试验/CTRI/2021/02/031016
CTRI/2021/02/031016尚未招募2 期

Efficacy of Majoon and Tila Barse Aswad in Lichen planus - An open labelled single arm clinical study

National Institute of Unani Medicine1 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2021年1月3日最近更新:

试验速览

阶段
2 期
状态
尚未招募
入组人数
23
试验地点
1
主要终点
1.Lichen Planus Severity Index18

研究概览

简要总结

Lichen planus(LP) is an idiopathic subacute or chronic inflammatory, Autoimmune, Mucocutaneous, Papulosquamous disorder that may affect the skin, scalp, nails and mucus membrane. Cutaneous lichen planus clinically characterized by distinctive violaceous, polygonal flat-topped pruritic papules which lines (Wickham’s striae) visible on the surface.

The exact incidence and prevalence of lichen planus are unknown, but the overall prevalence is believed to be somewhat 0.2% to 1% of the general population. Estimates between 0.14% and 0.27% have been reported worldwide and 0.38% in India. There is no sexual predilection and two- third of cases occurs between the 3rd and 6th decade of age4,6But Females are more prone to develop and  usually affecting in their 50s and 60s whereas males develop lichen planus at a somewhat earlier age. It develop adverse effects on quality of life in more than 90% of patients like psychological stress, social phobia, obsessive thoughts and cosmetologically disfigurement. There is strong association between depression and quality of life in both the gender.

In conventional medicine management of Lichen planus is challenging and can be discouraging for both, the patients and physician. Various oral drugs or topical corticosteroids have been used for treatment but many of recommended treatment lack conclusive evidence or efficacy and also show many side effects, drug resistance and interfere with immunity. So, alternative therapeutic approaches are being carried out. Through Unani herbal medicines could be solve by effective treatment with fewer side effects, enhance productivity, improve Quality of life.

In Unani System of medicine, direct description on LP is not available as such but according to its clinical presentation can be considered as Barse Aswad. The need of this study is to evaluate effectiveness of this classical unani preparation clinically, in this disease. So, Keeping all these in mind this study is planned for management of lichen planus with Unani medicine. Further according to the involvement of Madda we could relate it with khilt-e-saudawi (Melancholic humour).

So, according to this hypothesis it can be treated effectively with Majoon to expel out excessive and abnormal Sauda ( Melencholic Humour) from the whole body and appropriate Local application for symptomatic relief like itching and scaling etc. The Majoon used in this study contains Halela Siyah, Haleela Kabli, Aftimoon, Mawez munaqqa have Munzij Sauda Property and Tila Barse Aswad contains Barge Kaner, Mom, Gandhak and Roghan-e-kunjad to be administered orally and locally respectively.

Procedure of study**:** Patients with clinical features of LP fulfilling the inclusion criteria will be enrolled for the clinical trial. After obtaining their written informed consent and subsequently will be included in the study. The patients will be prescribed test drug in the form of Majoon orally and Tila for local application for 42 days with follow ups for assessment on every 14th day(14th day, 28th day, 42th day) . Before and after completion of trial, photographs of skin lesions will be taken for assessment  by an expert panel. The pre and post treatment objective findings (effects) will be assessed statistically.

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Open Label

入排标准

年龄范围
18.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • 1.Cases of Lichen Planus.
  • 2.Patients of both genders.
  • 3.Patients in the age group of 18 years to 60 years.
  • 4.Patients are willing to be a part of our study.

排除标准

  • 1.Patient below and above the age of 18 years and 60 years.
  • 2.Patient suffering from any other type of skin diseases like psoriasis, Eczema, Seborrheic Dermatitis, dermatophytosis, LSC and Lupus Erythematosus.
  • 3.Patient suffering from systemic and metabolic diseases like DM, severe asthma, Cardiac diseases, Chronic Renal failure.
  • 4.Pregnant & Lactating Women.
  • 5.Patients are not willing to be a part of study.

结局指标

主要结局

1.Lichen Planus Severity Index18

时间窗: At Baseline and at 6th week

2.Investigator assessment using Photograph

时间窗: At Baseline and at 6th week

3.Itching Severity on VAS20

时间窗: At Baseline and at 6th week

次要结局

  • 1.Dermatological Life Quality Index (DLQI)(At Baseline and 6th week)

研究者

申办方类型
Research institution and hospital

研究点 (1)

Loading locations...

相似试验